Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PF-08161842 in Healthy Adults
NCT07897708Phase 1Not yet recruiting
- Sponsor
- Pfizer
- Start
- Nov 2026
- Primary completion
- Mar 2027
01
Overview
Phase 1, randomised, double-blind trial of PF-08161842 in Alzheimer's disease (AD) (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Serious Adverse Events and 4 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
PF-08161842
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07897708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897708.